TY  - JOUR
AU  - Johnson, Melissa L
AU  - Zvirbule, Zanete
AU  - Laktionov, Konstantin
AU  - Helland, Aslaug
AU  - Cho, Byoung Chul
AU  - Gutierrez, Vanesa
AU  - Colinet, Benoît
AU  - Lena, Herve
AU  - Wolf, Martin
AU  - Gottfried, Maya
AU  - Okamoto, Isamu
AU  - van der Leest, Cor
AU  - Rich, Patricia
AU  - Hung, Jen-Yu
AU  - Appenzeller, Christina
AU  - Sun, Zhaowen
AU  - Maag, David
AU  - Luo, Yan
AU  - Nickner, Caroline
AU  - Vajikova, Alena
AU  - Komarnitsky, Philip
AU  - Bar, Jair
PY  - 2021
DO  - 10.1016/j.jtho.2021.03.012
UR  - http://hdl.handle.net/10668/17534
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, an atypical Notch ligand expressed in SCLC tumors. We evaluated the efficacy of Rova-T versus placebo as maintenance therapy in patients with extensive-stage-SCLC after...
LA  - en
KW  - DLL3
KW  - Maintenance
KW  - Phase 3
KW  - Platinum-based chemotherapy
KW  - Rovalpituzumab tesirine
KW  - Small cell lung cancer
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benzodiazepinones
KW  - Double-Blind Method
KW  - Humans
KW  - Immunoconjugates
KW  - Lung Neoplasms
KW  - Middle Aged
KW  - Platinum
TI  - Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
TY  - research article
VL  - 16
ER  -